ALSO NOTED: Caraco gets tentative nod for Zyrtec copycat; Critical Therapeutics launches pulmonary med;

> Caraco Pharmaceutical Laboratories got the FDA's tentative approval to sell a chewable form of the allergy med Zyrtec, whose patent expires in December. Release

> Critical Therapeutics has launched an inhalation treatment for chronic obstructive pulmonary disease. Report

> Beijing Med-Pharm is expanding its senior management team with a new vice president Yanping Zhao, who will oversee all the company's Chinese subsidiaries and handle corporate strategy such as mergers and acquisitions. Report

> Coley Pharmaceutical Group has adopted a shareholder rights plan to protect itself from hostile takeover, saying the plan wasn't prompted by any current takeover attempt. Release

> Jazz Pharmaceuticals added Kohlberg Kravis Roberts & Co. Principal Nathaniel Zilkha to its board. Release

And Finally... What's in a drug name? Oh, $200,000 to $500,000 in consulting costs. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.